KIORA PHARMACEUTICALS, INC. Debt Conversion, Converted Instrument, Amount
KIORA PHARMACEUTICALS, INC. (KPRX) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2016-03-30
- KIORA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-12-31 was $33.63K.
- KIORA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-09-30 was $217.75K.
- KIORA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- KIORA PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for fiscal 2014 was $1.40M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-03-30 | |||
| 2014-12-31 | $33.63K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $251.38K derived: sum of 2 quarters · filed 2016-03-30 | $1.40M 10-K · filed 2016-03-30 | |
| 2014-09-30 | $217.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $1.36M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $1.15M 10-Q · filed 2015-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |